Largest Contract Since Global Commercialization

"To Foster as a Global Blockbuster Drug"

Daewoong Pharmaceutical's diabetes treatment Enblo (ingredient name: Inavogliflozin) is set to enter the markets of eight major Middle Eastern and African (MENA) countries.


On July 2, Daewoong Pharmaceutical announced that it has signed an export supply agreement with Acino Pharma AG for Enblo targeting eight key countries in the Middle East and Africa, including Saudi Arabia and the United Arab Emirates. The total contract value, including milestone payments, is approximately 145.2 billion won, marking the largest deal since the global commercialization of Enblo.


Daewoong Pharmaceutical Enblo Global Package product. Daewoong Pharmaceutical

Daewoong Pharmaceutical Enblo Global Package product. Daewoong Pharmaceutical

View original image

This year, Daewoong Pharmaceutical plans to obtain product approval in Saudi Arabia and, starting in the first half of next year, sequentially secure approvals and launch Enblo in a total of eight countries, beginning with Saudi Arabia and including the United Arab Emirates, Qatar, Kuwait, Oman, Bahrain, Iraq, and Egypt.


The reason Daewoong Pharmaceutical selected this region is its unparalleled market potential. According to the International Diabetes Federation (IDF), one out of every six adults in the MENA region currently has diabetes, making it the largest market in the world in terms of prevalence. Pharmaceutical market research firm IQVIA reports that, last year, the total market size for diabetes treatments in Saudi Arabia, the United Arab Emirates, Kuwait, and Egypt reached 3.7946 trillion won.


Enblo is a domestically developed SGLT-2 inhibitor for type 2 diabetes that lowers blood sugar by inhibiting glucose reabsorption in the kidneys and promoting glucose excretion through urine. The drug is also gaining attention for its therapeutic benefits in the fields of kidney disease and heart failure, leading the company to believe it will be highly competitive in the MENA region.



Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, "This agreement is not only the largest global export deal for Enblo, but it is also significant as the first time a domestically developed SGLT-2 inhibitor diabetes treatment is entering the Middle Eastern and African markets. By collaborating with our partner Acino, which has proven commercial and sales capabilities in cardiovascular and metabolic diseases, we will rapidly expand Enblo’s presence in the Middle East and Africa and foster it into a global blockbuster drug."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing